FDA Clears Cresilon’s Novel TRAUMAGEL for Managing Moderate to Severe Bleeding

Cresilon has announced that its innovative device, TRAUMAGEL®, has received FDA clearance for temporary external use in controlling moderate to severe bleeding.

The revolutionary plant-based hemostatic gel technology is designed to stop and control life-threatening bleeding within seconds when applied to a wound at the point of care. 

TRAUMAGEL is an innovative hemostatic medical device that employs Cresilon's exclusive hydrogel technology. It has received FDA clearance for temporary external use in managing moderate to severe bleeding.

TRAUMAGEL is manufactured for the needs of the U.S. military, government health agencies, emergency medical services (EMS) systems, and medical professionals who routinely meet with traumatic wounds and need a solution to quickly stop and control severe bleeding.

Some hemostatic agents and gauze bandages are currently available for applications such as trauma and surgery, which takes more application time and can be difficult to apply, or not suitable for all types of bleeds. 

TRAUMAGEL® hemostatic gel is supplied in a pre-filled syringe, easy-to-apply, requires no preparation, and stops bleeding quickly across all types of bleeds.

This technology has a potential field and helps for pre-hospital treatment to reduce life-threatening brain hemorrhage and provide neuroprotection for penetrating traumatic brain injury ("TBI").

Source: https://www.prnewswire.com/news-releases/cresilon-receives-fda-clearance-for-traumagel-302222895.html